US SEC investigates cassava to develop dementia treatment… Suspicion of manipulation of research results


The U.S. Securities and Exchange Commission (SEC)

The Wall Street Journal reported that the U.S. Securities and Exchange Commission is investigating Cassava Science, a company that develops Alzheimer’s disease treatment allegations of manipulation.

According to the report, the allegations arose in August when two people, including former Johnson & Johnson neuroscience research director David Brett and Cornell Medical School professor Jeffrey Pitt Weil, filed a petition with the Food and Drug Administration (FDA) to suspend clinical trials of cassava. I lost.

They claimed that experimental images of cassava published in several scientific journals appeared to have been manipulated with software such as Photoshop.

He said that he short-selled the company’s stock, believing that the stock price would fall if investors became aware of the problem.

Cassava did not reveal the name of the specific institution on the 15th, but said it was cooperating with the government’s investigation over the allegations raised, but it did not mean that illegal activities were revealed.

Cassava CEO Remy Barbier also said that the US National Institutes of Health, which has supported cassava and an industry-academia cooperation group of about 23 billion won in Korean money, is also investigating the allegation since 2015 to develop the drug.

“There is no evidence that anyone, including me, was involved in this bizarre fraud,” Barbier said.

(Photo = US Securities and Exchange Commission website capture, Yonhap News)

Leave a Reply

Your email address will not be published. Required fields are marked *